In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC).

Watch the video and download the accompanying slides to learn about:

  • The considerations for treatment selection in clinical practice to minimise the impact on patients' lives
  • Applying recent data to treatment sequencing in bone-dominant mCRPC
  • Educating and supporting patients during treatment so they know what to expect

 

Clinical Takeaways

  • Radiopharmaceuticals such as radium-223 and 177Lu-PSMA-617 offer a survival benefit to mCRPC patients as well as managing bone pain and QOL

  • They are able to deliver targeted radiation to prostate cancer cells, thereby minimising toxicity to normal healthy tissue

  • Real-world data support using 177Lu-PSMA in patients who previously received Ra-223

  • Nurses and patients should be aware of post-treatment precautions, but radiopharmaceuticals are an effective and manageable treatment option for mCRPC patients

 

Janet Forgenie works at University College Hospital London as a Uro-oncology CNS managing patients with organ confined disease as well as metastatic disease having chemotherapy, radiotherapy and immunotherapy treatments primarily for prostate but also with bladder and penile cancer. She has a specialist interest in penile cancer patients who undergo extensive treatment regimens with complex health care needs. Over the years as a uro-oncology CNS Janet has been involved in setting up patient support groups and information seminars for radiotherapy patients which have proven very successful. She has also been involved in an exercise pilot for prostate patients on hormone treatments to encourage exercise to help manage some of the unpleasant side effects from hormones, such as bone health, body image and weight gain. Her background of diagnostic urology has helped extensively in the management of prostate cancer patients, and as a nurse prescriber Janet feels this has been invaluable in the development of a truly independent nurse led service. Janet started her nursing career in Canterbury Kent, achieving her Nursing Diploma in 1994 and Degree in 1997. During her nursing career Janet has worked primarily within urology and oncology, and her current role as a Uro-oncology CNS that combines both specialities is ideal. Janet’s urology experience has been extensive over the past 26 years, working with benign urology as well as oncology urology. She has experience with diagnostic urology, urodynamics and continence and bladder function and has also been involved in pathway development and service development. Janet also has three years of oncology experience, one of which was spent in Australia working with chemotherapy patients and the other two working on an inpatient chemotherapy ward.

Janet Forgenie has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bayer

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

GI-oncology-GI-CONNECT-10-years-thumbnail-GI2403 Video
Oncology 
Celebrating the 10th anniversary of GI CONNECT

10 years of independent medical education in GI oncology

Experts
Assoc. Prof. Gerald Prager, Assoc. Prof. Joleen Hubbard, Dr Thomas Winder, Prof. Andrea Sartore-Bianchi, Dr Dominik Modest
  • clock 2 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer